Reckitt Benckiser Group plc (OTCMKTS:RBGLY – Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 212,800 shares, a growth of 833.3% from the October 31st total of 22,800 shares. Based on an average daily volume of 1,855,900 shares, the short-interest ratio is presently 0.1 days.
Wall Street Analyst Weigh In
Several brokerages recently commented on RBGLY. UBS Group upgraded Reckitt Benckiser Group to a “strong-buy” rating in a report on Wednesday, September 18th. Sanford C. Bernstein cut shares of Reckitt Benckiser Group from a “strong-buy” rating to a “hold” rating in a report on Monday, November 4th. Citigroup raised shares of Reckitt Benckiser Group to a “strong-buy” rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. downgraded Reckitt Benckiser Group from an “overweight” rating to a “neutral” rating in a research note on Thursday, August 29th. Finally, Barclays raised shares of Reckitt Benckiser Group to a “strong-buy” rating in a research report on Friday, October 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Reckitt Benckiser Group has a consensus rating of “Moderate Buy”.
Get Our Latest Report on RBGLY
Reckitt Benckiser Group Stock Performance
Reckitt Benckiser Group Company Profile
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Recommended Stories
- Five stocks we like better than Reckitt Benckiser Group
- Investing in the High PE Growth Stocks
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What Are Dividend Contenders? Investing in Dividend Contenders
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What is the Shanghai Stock Exchange Composite Index?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.